NASDAQ
FULC

Fulcrum Therapeutics Inc

PHARMACEUTICAL PREPARATIONS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Fulcrum Therapeutics Inc Stock Price

Vitals

Today's Low:
$5.4800
Today's High:
$5.9350
Open Price:
$5.7900
52W Low:
$3.21
52W High:
$24.79
Prev. Close:
$5.8000
Volume:
318096

Company Statistics

Market Cap.:
$0.287 billion
Book Value:
3.92
Revenue TTM:
$0.014 billion
Operating Margin TTM:
-723%
Gross Profit TTM:
$-0.046 billion
Gross Profit TTM:
$-0.046 billion
Profit Margin:
0%
Return on Assets TTM:
-39.2%
Return on Equity TTM:
-76.7%

Company Profile

Fulcrum Therapeutics Inc had its IPO on 2019-07-18 under the ticker symbol FULC.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Fulcrum Therapeutics Inc has a staff strength of 0 employees.

Stock update

Shares of Fulcrum Therapeutics Inc opened at $5.79 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $5.48 - $5.94, and closed at $5.52.

This is a -4.83% slip from the previous day's closing price.

A total volume of 318,096 shares were traded at the close of the day’s session.

In the last one week, shares of Fulcrum Therapeutics Inc have increased by +10.4%.

Fulcrum Therapeutics Inc's Key Ratios

Fulcrum Therapeutics Inc has a market cap of $0.287 billion, indicating a price to book ratio of 1.758 and a price to sales ratio of 19.86.

In the last 12-months Fulcrum Therapeutics Inc’s revenue was $0.014 billion with a gross profit of $-0.046 billion and an EBITDA of $-0.102 billion. The EBITDA ratio measures Fulcrum Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Fulcrum Therapeutics Inc’s operating margin was -723% while its return on assets stood at -39.2% with a return of equity of -76.7%.

In Q2, Fulcrum Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 57%.

Fulcrum Therapeutics Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-2.385 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fulcrum Therapeutics Inc’s profitability.

Fulcrum Therapeutics Inc stock is trading at a EV to sales ratio of 8.86 and a EV to EBITDA ratio of -1.256. Its price to sales ratio in the trailing 12-months stood at 19.86.

Fulcrum Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Fulcrum Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Fulcrum Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Fulcrum Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Fulcrum Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Fulcrum Therapeutics Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$5.52
52-Week High
$24.79
52-Week Low
$3.21
Analyst Target Price
$26.88

Fulcrum Therapeutics Inc stock is currently trading at $5.52 per share. It touched a 52-week high of $24.79 and a 52-week low of $24.79. Analysts tracking the stock have a 12-month average target price of $26.88.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Fulcrum Therapeutics Inc

The stock symbol (also called stock or share ticker) of Fulcrum Therapeutics Inc is FULC

The IPO of Fulcrum Therapeutics Inc took place on 2019-07-18

Similar Industry Stocks (PHARMACEUTICAL PREPARATIONS)

Last Price
Chg
Chg%
$19.5
-0.72
-3.56%
$2.94
0.27
+9.96%
$21.75
-0.7
-3.12%
$1.73
0
0%
$12.14
-0.68
-5.3%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
$0.02
0.01
+100%
Oi S.A (OIBR-C)
$0
0
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA, US